Research suggests that the medication, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, originally developed to manage Type 2 diabetes, may be able to treat a wide range of conditions involving impulse control, like binge eating disorder.But although there may be tantalizing clues for helping patients with unwanted impulses, GLP-1 and GIP inhibitors may not be optimally designed to treat them sufficiently and need further research, according to a case study from the Perelman School of Medicine at the University of Pennsylvania, published today in Nature Medicine
Severe, persistent abdominal pain, especially radiating to the back, requires immediate medical attention as it may indicate pancreatitisa serious adverse effect noted in the FDA label
Sheahan KH, Wahlberg EA, Gilbert MP
Conversely, for women with polycystic ovary syndrome (PCOS) or obesity-related menstrual irregularities, weight loss can actually restore ovulatory cycles and improve period regularity
Adequate intake supports metabolism and consistent fat loss
The latest research continues to identify new variables that influence individual response
